|
| prognosis = 90% have significant problems despite treatment<ref name=MSD2021>{{cite web |title=Granulomatosis with Polyangiitis (GPA) - Musculoskeletal and Connective Tissue Disorders |url=https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa |website=MSD Manual Professional Edition |accessdate=11 April 2021 |language=en}}</ref>
| medication =
| treatment = [[immunosuppression|Immunosuppressive medications]] ([[rituximab]], [[cyclophosphamide]], [[corticosteroid]]s)<ref name=MSD2021>{{cite web |title=Granulomatosis with Polyangiitis (GPA) - Musculoskeletal and Connective Tissue Disorders |url=https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa |website=MSD Manual Professional Edition |accessdate=11 April 2021 |language=en}}</ref>
| prevention =
| differential = [[Microscopic polyangiitis]], [[eosinophilic granulomatosis with polyangiitis]], [[polyarteritis nodosa]]<ref name=NORD2021>{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref>
| diagnosis =
| causes = Unknown<ref name=Stat2021>{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref>
| image = Wegener's granulomatosis -b- intermed mag.jpg
| types =
| duration =
| onset = 40 to 60 yrs old<ref name=NORD2021 />
| onset = 40 to 60 yrs old<ref name=NORD2021>{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref>
| symptoms = Stuffy nose, [[epistaxis|nosebleeds]], [[uveitis|inflammation within the eye]], [[fever]], [[coughing up blood]], leg swelling, weight loss<ref name=Yates2017>{{cite journal|last1=Yates|first1=M|last2=Watts|first2=R|title=ANCA-associated vasculitis|journal=Clinical Medicine|date=February 2017|volume=17|issue=1|pages=60–64|doi=10.7861/clinmedicine.17-1-60|pmid=28148583|pmc=6297586|type=Review}}</ref><ref name=NORD2021>{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref>
| synonym = Wegener's granulomatosis (WG)
| specialty = [[Rheumatology]]
| deaths =
}}
'''ଗ୍ରାନୁଲୋମାଟୋସିସ ସହିତ''' ପଲିଆଞ୍ଜାଇଟିସ ( '''GPA''' '''),''' ପୂର୍ବ ନାମ '''ୱେଜେନର ଗ୍ରାନୁଲୋମାଟୋସିସ''' ( '''WG''' ), ଏକ ଦୀର୍ଘକାଳୀନ ରୋଗ ଯେଉଁଥିରେ ଗ୍ରାନୁଲୋମା ସୃଷ୍ଟି ଓ ରକ୍ତନଳୀରେ ପ୍ରଦାହ ହୁଏ । <ref name="Stat2021">{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref> <ref name="MSD2021">{{cite web |title=Granulomatosis with Polyangiitis (GPA) - Musculoskeletal and Connective Tissue Disorders |url=https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa |website=MSD Manual Professional Edition |accessdate=11 April 2021 |language=en}}</ref> ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ, ଫୁସଫୁସ ଓ [[ବୃକ୍କ|ବୃକ୍କରେ]] ଥିବା କ୍ଷୁଦ୍ର ଏବଂ ମଧ୍ୟମ ଆକାରର ରକ୍ତନଳୀମାନଙ୍କୁ ପ୍ରଭାବିତ କରିଥାଏ।<ref name="Stat2021">{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref> ସାଧାରଣ ଲକ୍ଷଣ ମଧ୍ୟରେ ନାକ ବନ୍ଦ, [[ନାକରୁ ରକ୍ତସ୍ରାବ]] ଏବଂ ଆଖି ଭିତରେ ପ୍ରଦାହ ଦେଖାଯାଏ । <ref name="Yates2017">{{cite journal|last1=Yates|first1=M|last2=Watts|first2=R|title=ANCA-associated vasculitis|journal=Clinical Medicine|date=February 2017|volume=17|issue=1|pages=60–64|doi=10.7861/clinmedicine.17-1-60|pmid=28148583|pmc=6297586|type=Review}}</ref> ଅନ୍ୟ ଲକ୍ଷଣ ମଧ୍ୟରେ [[ଜ୍ୱର]], କାଶରେ ରକ୍ତ ପଡ଼ିବା, ଗୋଡ ଫୁଲିଯିବା ଏବଂ ଓଜନ ହ୍ରାସ ହୋଇପାରେ। <ref name="NORD2021">{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref> ଲକ୍ଷଣ ଧିର କିମ୍ବା କ୍ଷିପ୍ର ହୋଇପାରେ। <ref name="NORD2021">{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref> ରୋଗ ଜଟିଳ ହେଲେ [[ଶ୍ରବଣହାନୀ]], [[ଦୃଷ୍ଟିହାନି|ଦୃଷ୍ଟିହାନୀ]], ସଂକ୍ରମଣ ଏବଂ [[ବୃକ୍କ ବିଫଳତା|କିଡନୀ ବିଫଳତା]] ହୋଇପାରେ | <ref name="Stat2021">{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref>
ଏହାର ପ୍ରକୃତ କାରଣ ଅସ୍ପଷ୍ଟ, ଯଦିଓ ଏହା ଜେନେଟିକ ଓ ପରିବେଶ ଯୋଗୁ ହେଉଥିବା ବିଶ୍ୱାସ କରାଯାଏ | <ref name="Stat2021">{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref> <ref>{{Cite web|url=https://rarediseases.info.nih.gov/diseases/7880/granulomatosis-with-polyangiitis|title=Granulomatosis with polyangiitis {{!}} Genetic and Rare Diseases Information Center (GARD) – an NCATS Program|website=rarediseases.info.nih.gov|access-date=11 April 2021}}</ref> ଏହା ବ୍ୟକ୍ତିର ପିତାମାତାଙ୍କଠାରୁ ଉତ୍ତରାଧିକାର ସୂତ୍ରରେ ଆସେନି ।<ref name="NORD2021">{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref> ଏହା ଏକ ପ୍ରକାର [[ଅଟୋଇମ୍ମ୍ୟୁନ ଡିଜିଜ|ଅଟୋଇମ୍ୟୁନ ଡିଜିଜ]], ବିଶେଷ ଭାବରେ ଏଏନସିଏ-ଜଡ଼ିତ ଭାସ୍କୁଲାଇଟିସ ଏବଂ ପଲିଆଞ୍ଜାଇଟିସ ସହିତ ମାଇକ୍ରୋସ୍କୋପିକ ଗ୍ରାନୁଲୋମାଟୋସିସ ।<ref name="Stat2021">{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref> <ref name="NORD2021">{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref> ଲକ୍ଷଣ ଅନୁଶୀଳନ ଏବଂ ଲାବୋରେଟୋରୀ ପରୀକ୍ଷଣ ଉପରେ ଆଧାର କରି ରୋଗ ନିର୍ଣ୍ଣୟ କରାଯାଇପାରେ ଏବଂ ତନ୍ତୁ ବାୟୋପ୍ସି କରି ରୋଗ ନିଶ୍ଚିତ କରାଯାଇଥାଏ। <ref name="NORD2021">{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref>
ରୋଗର ଗମ୍ଭୀରତା ଉପରେ ଚିକିତ୍ସା ନିର୍ଭର କରେ | <ref name="MSD2021">{{cite web |title=Granulomatosis with Polyangiitis (GPA) - Musculoskeletal and Connective Tissue Disorders |url=https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa |website=MSD Manual Professional Edition |accessdate=11 April 2021 |language=en}}</ref> <ref name="Lal2015">{{Cite journal|last=Lally|first=L|last2=Spiera|first2=R|date=2015|title=Current therapies for ANCA-associated vasculitis|journal=Annual Review of Medicine|type=Review|volume=66|pages=227–40|doi=10.1146/annurev-med-011514-023051|pmid=25341007}}</ref> ଲକ୍ଷଣ ଉପଶମ ନିମନ୍ତେ [[ରିଟକ୍ସିମାବ]] ବା ସାଇକ୍ଲୋଫୋସ୍ଫାମାଇଡ ଭଳି ଇମ୍ମ୍ୟୁନୋସପ୍ରେସିଭ ଔଷଦ ଏବଂ ଉଚ୍ଚ ମାତ୍ରାର କର୍ଟିକୋଷ୍ଟିରଏଡ ଦିଆଯାଏ ।<ref name="MSD2021">{{cite web |title=Granulomatosis with Polyangiitis (GPA) - Musculoskeletal and Connective Tissue Disorders |url=https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa |website=MSD Manual Professional Edition |accessdate=11 April 2021 |language=en}}</ref> ରୋଗକୁ ନିୟନ୍ତ୍ରଣରେ ରଖିବା ପାଇଁ [[ଆଜାଥାଇଓପ୍ରିନ|ଆଜାଥାଓପ୍ରିନ]], [[ମେଥୋଟ୍ରେକ୍ସେଟ]] କିମ୍ବା ରିଟକ୍ସିମାବ ବ୍ୟବହାର କରାଯାଇପାରେ | <ref name="MSD2021">{{cite web |title=Granulomatosis with Polyangiitis (GPA) - Musculoskeletal and Connective Tissue Disorders |url=https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa |website=MSD Manual Professional Edition |accessdate=11 April 2021 |language=en}}</ref> <ref name="Sing2017">{{Cite journal|last=Singer|first=O|last2=McCune|first2=WJ|date=May 2017|title=Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis|journal=Current Opinion in Rheumatology|type=Review|volume=29|issue=3|pages=248–53|doi=10.1097/BOR.0000000000000382|pmid=28306595}}</ref> ବୃକ୍କରେ ଦୋଷ ଥିଲେ ପ୍ଲାଜ୍ମା ବିନିମୟ ବ୍ୟବହୃତ ହୋଇପାରେ | <ref name="Walt2020">{{Cite journal|last=Walters|first=GD|last2=Willis|first2=NS|last3=Cooper|first3=TE|last4=Craig|first4=JC|date=13 January 2020|title=Interventions for renal vasculitis in adults.|journal=The Cochrane database of systematic reviews|volume=1|pages=CD003232|doi=10.1002/14651858.CD003232.pub4|pmid=31927782}}</ref> ଚିକିତ୍ସା ବିନା ବଞ୍ଚିବା ଦୁଷ୍କର; ତଥାପି, ଚିକିତ୍ସା ସହିତ ଅଧିକାଂଶ ରୋଗୀ ୮ ବର୍ଷରୁ ଅଧିକ ବଞ୍ଚନ୍ତି | <ref name="Stat2021">{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref>
ୟୁରୋପରେ ପ୍ରତି ଏକ ନିୟୁତ ଲୋକଙ୍କ ମଧ୍ୟରୁ ୨-୪ ନୂତନ ରୋଗୀ ଚିହ୍ନଟ ହୁଅନ୍ତି ।<ref name="Yates2017">{{cite journal|last1=Yates|first1=M|last2=Watts|first2=R|title=ANCA-associated vasculitis|journal=Clinical Medicine|date=February 2017|volume=17|issue=1|pages=60–64|doi=10.7861/clinmedicine.17-1-60|pmid=28148583|pmc=6297586|type=Review}}</ref> ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ପ୍ରତି ୧୦୦,୦୦୦ ଲୋକଙ୍କ ମଧ୍ୟରୁ ପ୍ରାୟ ୩ ଜଣ ପ୍ରଭାବିତ ହୁଅନ୍ତି । <ref name="Pak2015">{{Cite journal|last=Pakalniskis|first=MG|last2=Berg|first2=AD|last3=Policeni|first3=BA|last4=Gentry|first4=LR|last5=Sato|first5=Y|last6=Moritani|first6=T|last7=Smoker|first7=WR|date=December 2015|title=The Many Faces of Granulomatosis With Polyangiitis: A Review of the Head and Neck Imaging Manifestations|journal=AJR. American Journal of Roentgenology|type=Review|volume=205|issue=6|pages=W619–29|doi=10.2214/AJR.14.13864|pmid=26587951}}</ref> ରୋଗର ଆରମ୍ଭ ପ୍ରାୟଃ ୪୦ରୁ ୬୦ ବର୍ଷ ବୟସ ମଧ୍ୟରେ ହୋଇଥାଏ | <ref name="NORD2021">{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref> ପୁରୁଷ ଏବଂ ସ୍ତ୍ରୀ ସମାନ ଭାବରେ ପ୍ରଭାବିତ ହୁଅନ୍ତି | <ref name="NORD2021">{{cite web |title=Granulomatosis with Polyangiitis |url=https://rarediseases.org/rare-diseases/granulomatosis-with-polyangiitis/ |website=NORD (National Organization for Rare Disorders) |accessdate=11 April 2021}}</ref> [[ଜାପାନ]] ଏବଂ ଆଫ୍ରିକୀୟ-ଆମେରିକୀୟ ବାସିନ୍ଦାଙ୍କର ଏହି ରୋଗ କ୍ୱଚିତ ହୁଏ ।<ref name="Mill2013">{{Cite journal|last=Millet|first=A|last2=Pederzoli-Ribeil|first2=M|last3=Guillevin|first3=L|last4=Witko-Sarsat|first4=V|last5=Mouthon|first5=L|date=August 2013|title=Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?|journal=Annals of the Rheumatic Diseases|type=Review|volume=72|issue=8|pages=1273–9|doi=10.1136/annrheumdis-2013-203255|pmid=23606701}}</ref> ଏହି ରୋଗ ପ୍ରଥମେ ୧୯୩୧ ମସିହାରେ ହେଞ୍ଜ କିସିଞ୍ଜର ବର୍ଣ୍ଣନା କରିଥିଲେ ମଧ୍ୟ ୧୯୩୬ ମସିହା ପର୍ଯ୍ୟନ୍ତ ଏହା ଏକ ପୃଥକ ରୋଗ ଭାବରେ ଚିହ୍ନଟ ହୋଇନଥିଲା। <ref name="Stat2021">{{cite journal |last1=Garlapati |first1=P |last2=Qurie |first2=A |title=Granulomatosis with Polyangiitis |date=January 2021 |pmid=32491759}}</ref>
== ଆଧାର ==
<references />
[[ଶ୍ରେଣୀ:ଚିକିତ୍ସା ବିଜ୍ଞାନ]]
[[Category:Translated from MDWiki]]
| 